BIO-B
Bio-Rad Laboratories, Inc.
Set alert
- YTD
- +22.14%
- 1 year
- +25.19%
- Open
- 379.50
- Prev close
- 379.50
- Mkt cap
- 10.15B
- Vol
- 13
- Avg vol
- 9
- EPS
- 7.89
- P/E
- 48.10
- Div yield
- 0.00%
More statistics
- Low
- 379.50
- High
- 379.50
- Forward P/E
- 0.00
- Beta
- 1.07
- Short ratio
- 1.00
- Inst. own
- 0.04%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 365.78
- 200-d avg
- 310.70
- 1y target
- 0.00
Key statistics
- Market cap
- 10.16B
- Enterprise value
- 9.90B
- Trailing P/E
- 48.10
- Forward P/E
- 0.00
- PEG ratio
- 4.23
- Price / sales
- 3.92
- Price / book
- 1.41
- EPS (TTM)
- 7.89
- Beta
- 1.07
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 8.59%
- Revenue (TTM)
- 2.59B
- Revenue growth
- -0.10%
- Free cash flow
- 283.19M
- Total cash
- 1.62B
- Total debt
- 1.37B
- Return on equity
- 3.11%
- Shares outstanding
- 5.06M
- Short % of float
- 0.00%
- 50-day average
- 365.78
- 200-day average
- 310.70
Analyst view
Consensus: none
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | 2.23 | — | — | — |
| Aug 4, 2026 | Jun 30, 2026 | 1.78 | 2.62 | +0.84 | +47.19% |
| Apr 30, 2026 | Mar 31, 2026 | 2.01 | 1.89 | -0.12 | -5.97% |
| Feb 12, 2026 | Dec 31, 2025 | 2.69 | 2.51 | -0.18 | -6.69% |
| Oct 29, 2025 | Sep 30, 2025 | 1.89 | 2.26 | +0.37 | +19.58% |
| Jul 31, 2025 | Jun 30, 2025 | 1.75 | 2.61 | +0.86 | +49.14% |
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- bio-rad.com
News
- Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause
- Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings
- Bio-Rad Laboratories beats quarterly profit estimates on strong sales in diagnostics unit
- Bio-Rad Labs cuts annual revenue forecast on weak demand for diagnostics products
- Bio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slip
- Bio-Rad Labs cuts 2023 revenue growth forecast as biotechs cut spending
Your note
Sign in to keep a note on BIO-B — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Flow Traders U.S. LLC | 0.02% | 760 | 288.42K | Jun 29, 2026 |
| Morgan Stanley | 0.01% | 712 | 270.20K | Jun 29, 2026 |
| Whittier Trust Company | 0.00% | 160 | 60.72K | Jun 29, 2026 |
| UBS Group AG | 0.00% | 13 | 4.93K | Jun 29, 2026 |
| Wells Fargo & Company | 0.00% | 170 | 64.52K | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Gabelli Global Small & Mid Cap Value Trust | 0.00% | 150 | 56.92K | Sep 29, 2026 |